> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tirzepatide reduced BMI by 18.5% over 72 weeks in adolescents with obesity
- URL: https://www.coios.me/tirzepatide-reduced-bmi-by-18-5-over-72-weeks-in/
- Published: 2026-11-18T13:18:12.000Z
- Updated: 2026-11-18T13:55:16.000Z
- Description: In 160 adolescents with obesity, weekly tirzepatide cut BMI by 18.5% over 72 weeks, against a 0.5% rise with placebo.
- Author: Daniel Ryan
- Tags: Health today, Obesity, diabetes and GLP-1, Canada, Czechia, Israel, Italy, Poland, United States, #peer-reviewed, #new, #item, #source-2026-11, #score-78

This phase 3 trial tested weekly tirzepatide in 160 adolescents with obesity, or overweight plus a complication. Across 31 centres in six countries, they were randomised 2:1, double-blind, to tirzepatide or placebo plus lifestyle intervention. At week 72, BMI fell 18.5% with tirzepatide and rose 0.5% with placebo, a 19.0-point difference. BMI fell by at least 5% in 79.6% on tirzepatide and 28.5% on placebo. All 10 key secondary outcomes, including body weight, waist circumference and physical functioning, favoured tirzepatide. Adverse events and discontinuations were recorded, but the abstract supplied ends before reporting them.

*Why it is interesting: Tirzepatide is approved for obesity management in adults. This placebo-controlled trial reports its 72-week effect on BMI in adolescents.*

Source

[JAMA, 15 November 2026](https://doi.org/10.1001/jama.2026.23420?ref=coios.me)

DOI

10.1001/jama.2026.23420

Type

Peer-reviewed article

Design

Phase 3 randomised double-blind placebo-controlled trial, 160 adolescents aged 12 to <18, 2:1 allocation, 72 weeks, 31 centres, 2023-2026

Verdict

New finding

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)